English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 19 January 2022, 17:36 JST
Share:
    

Source: Eisai
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
Highest Ranked Global Pharmaceutical Company

TOKYO, Jan 19, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been listed in the 2022 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's sixth inclusion on the list. Ranked 32nd, Eisai was the highest ranking company among global pharmaceutical companies.

The Global 100 evaluates the sustainability of approximately 6,900 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year. The Global 100 is based on up to 24 key performance indicators covering ESG initiatives, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels. Eisai received high evaluation particularly on clean revenue and investment* and maintenance of work environment that ensures safety and health of employees.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) corporate philosophy, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.

*Sales revenue, R&D cost and investment for products such as medicines which are under equitable pricing strategies and included in the WHO Essentials Medicines Lists or used to treat any of in scope diseases, conditions and pathogens defined by the ATM Index Foundation.


Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Releated News
2022年5月10日 11時00分 JST
エーザイ、抗アミロイドβ(Aβ)プロトフィブリル抗体「レカネマブ」について、米国において、迅速承認制度に基づく早期アルツハイマー病に対する生物製剤ライセンス申請の段階的申請を完了
2022年5月10日 11時00分 JST
エーザイ、筋萎縮性側索硬化症(ALS)に対する高用量メコバラミン製剤の医師主導治験の結果を踏まえて、日本における新薬承認申請に向けた作業を開始
Tuesday, 10 May 2022, 11:23 JST
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
Tuesday, 10 May 2022, 11:00 JST
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
2022年4月28日 10時00分 JST
エーザイ、企業価値・株主共同の利益の確保に関する対応方針(買収防衛策)の非継続(廃止)について
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575